TB-500: Peptide Identity, Research Terminology and Analytical Documentation
TB-500 appears in analytical research literature as a name associated with an N-terminally acetylated fragment of thymosin beta-4: Ac-LKKTETQ. When reviewing a paper or a research material, the name alone is not enough. The sequence, terminal modifications and analytical evidence need to match.
This guide explains how to read TB-500 terminology, distinguish the studied fragment from its parent peptide and evaluate the documentation accompanying a laboratory research material. It does not describe human or veterinary use.
What does TB-500 refer to in the research literature?
A 2012 characterization study identified Ac-LKKTETQ in the TB-500 product examined by the investigators. The researchers used high-performance liquid chromatography with high-resolution mass spectrometry and synthesized the peptide to support structural characterization. Their finding identifies the material they analyzed; it does not establish the composition of every material carrying the same name. Source: Esposito and colleagues, Drug Testing and Analysis, 2012.
The sequence LKKTETQ contains seven amino acid residues and corresponds to positions 17–23 of thymosin beta-4. The prefix “Ac-” indicates N-terminal acetylation. An unmodified sequence and an acetylated sequence should not be treated as interchangeable identifiers.
Is TB-500 the same as thymosin beta-4?
The fragment characterized in that study is not the full-length parent peptide. A shared sequence region does not make two molecules identical. When a source uses “TB-500” and “thymosin beta-4” together, check which molecular entity was actually studied before applying its findings.
A useful reading checklist is:
- Sequence: which residues are present?
- Terminal groups: is acetylation or another modification specified?
- Material: did the experiment use an isolated fragment, the parent peptide or a formulated sample?
- Evidence: which measurements support the assigned identity?
What have analytical TB-500 studies measured?
A separate 2012 study developed a liquid chromatography–mass spectrometry method to detect N-acetylated LKKTETQ and its metabolites in equine urine and plasma. Its relevance here is analytical: it illustrates how investigators distinguish a target peptide and related analytes within a biological sample. Source: Ho and colleagues, Journal of Chromatography A, 2012.
A detection method answers a different question from a biological experiment. Detecting a peptide does not establish a therapeutic effect, and identifying metabolites does not validate the identity or purity of a separate supplier’s lot. Findings should remain tied to the material, model and endpoint reported in the original paper.
What documentation matters for a TB-500 research material?
Before comparing materials, ask for documentation that makes the chemical identity explicit. “TB-500” should be accompanied by a stated sequence and terminal modifications, rather than serving as the only identifier.
- Lot connection: does the report identify the same batch as the supplied material?
- Assigned identity: are the peptide sequence, modifications and chemical form stated?
- Identity evidence: what method was used, and what result supports the assignment?
- Purity: which chromatographic method and reporting basis produced the stated result?
- Content: is a separate quantitative content measurement available when required by the research?
- Traceability: are the report date, laboratory and relevant method details provided?
This is a suggested review framework, not a claim that every supplier performs these tests. For a broader walkthrough, read How to Read a Certificate of Analysis for Research Compounds.
Why separate identity, purity and content?
These terms address different questions. Identity concerns what the material is. A chromatographic purity result describes the sample within the scope of the stated method. Content concerns how much of the specified analyte is present on a defined reporting basis.
Reviewing all three questions is more informative than relying on a single percentage. Our guide to HPLC purity and assay explains the distinction. For another example of sequence-led literature review, see the BPC-157 research overview.
Frequently asked questions
What sequence was identified in the published TB-500 characterization study?
The investigators identified Ac-LKKTETQ, an N-terminally acetylated seven-residue fragment corresponding to thymosin beta-4 positions 17–23.
Can findings about thymosin beta-4 automatically be assigned to its fragment?
No. Confirm the exact molecule, experimental model and measured endpoint. A shared sequence region does not establish equivalent behavior.
Does a published paper verify a supplier’s TB-500 lot?
No. The paper concerns its own experimental material. A separate lot needs relevant, lot-specific analytical documentation.
Is this article guidance for human or veterinary use?
No. This article concerns research terminology and analytical documentation for laboratory materials. It makes no claim of safety or effectiveness for human or veterinary use.
References
- Esposito et al. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500. Drug Testing and Analysis, 2012. DOI: 10.1002/dta.1402.
- Ho et al. Doping control analysis of TB-500 in equine urine and plasma by liquid chromatography–mass spectrometry. Journal of Chromatography A, 2012.
CONTINUE WITH AUREVIA
Your next research step.
Conducting laboratory research? Create a research account, or ask us about material identity and lot-specific analytical documentation.
For laboratories and independent individuals conducting genuine laboratory research. First orders are verified before shipping. Not for human or veterinary use.